Navigation Links
Gene variations that alter key enzyme linked to prostate cancer
Date:10/1/2010

Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.

The genetic variations all impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate a cell's responses to hormones and other signals. Previous studies by NIH researchers have linked genetic variations that inactivate PDE11A with increased susceptibility to testicular cancer and adrenal tumors

The researchers found that a group of men with prostate cancer were nearly four times more likely to have variations affecting the activity of PDE11A than did men who did not have prostate cancer. In 2010, it is estimated that there will be 217,730 new cases of prostate cancer, and 32,050 deaths (http://www.cancer.gov/cancertopics/types/prostate).

"Our study indicates that PDE11A one day may have a place in genetic screening for predisposition to prostate cancer," said the senior author of the study, Constantine Stratakis, M.D., D.Sc., acting director of the Intramural Research program at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Dr. Stratakis's research team included colleagues at the NICHD, first author Fabio Rueda Faucz and colleagues from the Pontifical Catholic University of Parana, Brazil; the Cochin Institute in Paris; and A.C. Camargo Hospital in Sao Paulo. The investigators also received support from the Parana State Secretariat of Science, Technology and Higher Education.

The findings were published online in the Journal of Clinical Endocrinology and Metabolism.

The researchers examined tissue from 50 men with prostate cancer and 287 men who did not have prostate cancer. The researchers analyzed the DNA of the men and found 8 variations in the PDE11A gene that decreased the production or activity of PDE11A. Of the men with prostate cancer, 30 percent had one or more of these variations, compared with 10 percent of the men who did not have prostate cancer. Of the variations the researchers detected, 5 had been detected in previous studies and 3 were previously unknown.

Dr. Stratakis explained that phosphodiesterase enzymes, of which there are nearly a dozen, regulate cellular activity in hormone producing organs such as the testes, prostate gland, adrenal gland and ovaries. PDE11A regulates cyclic adenosine monophosphate, a compound involved in supplying cells with energy.

Tadalafil, a drug used to treat erectile dysfunction, also inhibits PDE11A. The researchers called for future studies to determine if tadalafil or other drugs that inhibit PDE11A might affect the prostate in men who have a variant gene for PDE11A.

There is no current clinical evidence to date linking tadalafil to prostate cancer or to other cancers.


'/>"/>

Contact: Robert Bock
bockr@mail.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development
Source:Eurekalert

Related biology news :

1. U of MN study shows link between gene variations and cancer survival
2. Scientists uncover new genetic variations linked to psoriasis
3. The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders
4. Study finds variations in 1 gene may be associated with endurance running
5. Variations on the genetic theme
6. Rare and common genetic variations responsible for high triglyceride levels in blood
7. Alternative to burning: environmentally sound disposal for wood chips
8. During exercise, the human brain shifts into high gear on alternative energy
9. Earthworm activity can alter forests carbon-carrying capabilities
10. Social interactions can alter gene expression in the brain, and vice versa
11. Turtles alter nesting dates due to temperature change says ISU researcher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... ... 25, 2017 , ... In this webinar , which ... considerations needed for designing ideal guide RNAs and DNA oligo or plasmid repair ... double-strand breaks in genomic DNA has greatly simplified strategies for precise gene editing ...
(Date:7/26/2017)... ... 2017 , ... Joni Rutter, Director of Scientific Programs of ... will be one of the esteemed presenters at the 9th Annual Personalized and ... on the latest advancements in the precision and personalized medicine field. The 9th ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... Heinz as Executive Director of Strategic Planning. His extensive background in consulting, ... Chuck’s professional experience encompasses marketing and differentiation consulting, business strategy development, new ...
(Date:7/24/2017)... ... July 24, 2017 , ... Each year, ... who have proven their superior service quality as rated by hiring professionals and ... industry leader based on service quality ratings from their placed talent. , Fewer ...
Breaking Biology Technology: